Spots Global Cancer Trial Database for Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Official Title: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer: a Multicenter, Retrospective Study
Study ID: NCT05572645
Conditions
Study Description
Brief Summary: Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab
Detailed Description: This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab in patients with HER2-positive metastatic breast cancer.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
